

Valeant Pharmaceuticals to Host Investor Day

June 21, 2012

Reaffirms Annual Financial Guidance for 2012, expect to be at upper end

MONTREAL, June 21, 2012 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) will be hosting an Investor Day today in Florham Park, New Jersey where the Company will be discussing certain business operations, organic growth calculations and other performance metrics, including the Company's quarterly performance trends. In addition, Valeant is reaffirming its financial guidance for 2012 provided in its press release dated May 3, 2012, at the upper end of the range. This guidance does not include recently announced or not yet closed acquisitions such as Natur Produkt, Acne Free, Swiss Herbal and OraPharma.

A webcast of the presentations, along with the powerpoint presentations, is available through Valeant's website,

www.valeant.com

, live from 8:30 a.m. ET to 12:30 p.m. ET today and on replay afterwards.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

www.valeant.com

.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding our financial guidance. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission (the "SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Note on Financial Guidance

The reaffirmation of the Company's previous financial guidance issued on May 3, 2012, is effective only as of the date hereof, June 21, 2012, and will not be updated or confirmed until the Company publicly announces updated or affirmed guidance.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.



Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com
908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

